|
1
|
Claret FX, Hibi M, Dhut S, Toda T and
Karin M: A new group of conserved coactivators that increase the
specificity of AP-1 transcription factors. Nature. 383:453–457.
1996. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shackleford TJ and Claret FX: JAB1/CSN5: A
new player in cell cycle control and cancer. Cell Div. 5:262010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oh W, Lee EW, Sung YH, Yang MR, Ghim J,
Lee HW and Song J: Jab1 induces the cytoplasmic localization and
degradation of p53 in coordination with Hdm2. J Biol Chem.
281:17457–17465. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang XC, Chen J, Su CH, Yang HY and Lee
MH: Roles for CSN5 in control of p53/MDM2 activities. J Cell
Biochem. 103:1219–1230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim BC, Lee HJ, Park SH, Lee SR, Karpova
TS, McNally JG, Felici A, Lee DK and Kim SJ: JAB1/CSN5, a component
of the COP9 signalosome, regulates transforming growth factor beta
signaling by binding to Smad7 and promoting its degradation. Mol
Cell Biol. 24:2251–2262. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim JH, Choi JK, Cinghu S, Jang JW, Lee
YS, Li YH, Goh YM, Chi XZ, Lee KS, Wee H and Bae SC: JAB1/CSN5
induces the cytoplasmic localization and degradation of RUNX3. J
Cell Biochem. 107:557–565. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tomoda K, Kubota Y and Kato J: Degradation
of the cyclin-dependentkinase inhibitor p27Kip1 is
instigated by Jab1. Nature. 398:160–165. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tomoda K, Kubota Y, Arata Y, Mori S, Maeda
M, Tanaka T, Yoshida M, Yoneda-Kato N and Kato JY: The cytoplasmic
shuttling and subsequent degradation of p27Kip1 mediated
by JAB1/CSN5 and the COP9 signalosome complex. J Biol Chem.
277:2302–2310. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM,
Bae SK, Park JW, Kim KR and Kim KW: Jab1 interacts directly with
HIF-1alpha and regulates its stability. J Biol Chem. 277:9–12.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bemis L, Chan DA, Finkielstein CV, Qi L,
Sutphin PD, Chen X, Stenmark K, Giaccia AJ and Zundel W: Distinct
aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5.
Genes Dev. 18:739–744. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishimoto A, Kugimiya N, Hosoyama T, Enoki
T, Li TS and Hamano K: JAB1 regulates unphosphorylated STAT3
DNA-binding activity through protein-protein interaction in human
colon cancer cells. Biochem Biophys Res Commun. 438:513–518. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shackleford TJ, Zhang Q, Tian L, Vu TT,
Korapati AL, Baumgartner AM, Le XF, Liao WS and Claret FX: Stat3
and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate
Jab1/CSN5 expression in mammary carcinoma cells. Breast Cancer Res.
13:R652011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu MC, Chang HC and Hung WC: HER-2/neu
transcriptionally activates Jab1 expression via the
AKT/beta-catenin pathway in breast cancer cells. Endocr Relat
Cancer. 14:655–667. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sui L, Dong Y, Watanabe Y, Yamaguchi F,
Sugimoto K and Tokuda M: Clinical significance of Skp2 expression,
alone and combined with Jab1 and p27 in epithelial ovarian tumors.
Oncol Rep. 15:765–771. 2006.PubMed/NCBI
|
|
15
|
Sui L, Dong Y, Ohno M, Watanabe Y,
Sugimoto K, Tai Y and Tokuda M: Jab1 expression is associated with
inverse expression of p27 (kip1) and poor prognosis in epithelial
ovarian tumors. Clin Cancer Res. 7:4130–4135. 2001.PubMed/NCBI
|
|
16
|
Harada K, Kawashima Y, Yoshida H and Sato
M: High expression of Jun activation domain-binding protein 1
(Jab1) is a strong prognostic marker in oral squamous cell
carcinoma patients treated by UFT in combination with radiation.
Anticancer Res. 26:1615–1619. 2006.PubMed/NCBI
|
|
17
|
Dong Y, Sui L, Watanabe Y, Yamaguchi F,
Hatano N and Tokuda M: Prognostic significance of Jab1 expression
in laryngeal squamous cell carcinomas. Clin Cancer Res. 11:259–266.
2005.PubMed/NCBI
|
|
18
|
Wang Y, Yu YN, Song S, Li TJ, Xiang JY,
Zhang H, Lu MD, Ji F and Hu LQ: JAB1 and phospho-Ser10 p27
expression profile determine human hepatocellular carcinoma
prognosis. J Cancer Res Clin Oncol. 140:969–978. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He SM, Zhao ZW, Wang Y, Zhao JP, Wang L,
Hou F and Gao GD: Potential role of Jun activation domain-binding
protein 1 and phosphorylated p27 expression in prognosis of glioma.
Brain Tumor Pathol. 29:3–9. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sorbye SW, Kilvaer TK, Valkov A, Donnem T,
Smeland E, Al-Shibli K, Bremnes RM and Busund LT: Prognostic impact
of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLoS
One. 7:e470682012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fukumoto A, Ikeda N, Sho M, Tomoda K,
Kanehiro H, Hisanaga M, Tsurui Y, Tsutsumi M, Kato JY and Nakajima
Y: Prognostic significance of localized p27Kip1 and
potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep.
11:277–284. 2004.PubMed/NCBI
|
|
22
|
Wang F, Wang Y, Yu X, Yang D, Wang Z, Lu
C, Yuan Z, Xiao M and Shen A: Significance of Jab1 expression in
human esophageal squamous cell carcinoma. J Clin Gastroenterol.
43:520–526. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Osoegawa A, Yoshino I, Kometani T,
Yamaguchi M, Kameyama T, Yohena T and Maehara Y: Overexpression of
Jun activation domain-binding protein 1 in nonsmall cell lung
cancer and its significance in p27 expression and clinical
features. Cancer. 107:154–161. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Fei M, Cheng C, Zhang D, Lu J, He
S, Zhao Y, Wang Y and Shen A: Jun activation domain-binding protein
1 negatively regulate p27 kip1 in non-Hodgkin's lymphomas. Cancer
Biol Ther. 7:460–467. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu T, Su B, Wang C, Wang S, Huang H, Pan
Y, Wang D, Wei W, Claret FX and Yang H: Molecular markers to assess
short-term disease local recurrence in nasopharyngeal carcinoma.
Oncol Rep. 33:1418–1426. 2015. View Article : Google Scholar : PubMed/NCBI
|
